0HIY Stock Chart & Stats
$8.90
-$0.05(-0.63%)
At close: 4:00 PM EDT
$8.90
-$0.05(-0.63%)
Day’s Range― - ―
52-Week Range$4.02 - $19.05
Previous CloseN/A
Volume137.00
Average Volume (3M)1.04K
Market Cap
$94.15M
Enterprise Value$214.12
Total Cash (Recent Filing)$9.87M
Total Debt (Recent Filing)$9.88M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Oct 29, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.18
Shares Outstanding10,037,710
10 Day Avg. Volume873
30 Day Avg. Volume1,036
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)-5.89
Price to Sales (P/S)1.88
P/FCF Ratio-4.45
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$15.50Price Target Upside74.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.71
Revenue Forecast (FY)$2.82M
Bulls Say, Bears Say
Bulls Say
High Gross MarginA high gross margin indicates that the underlying economics of successful programs can be attractive once development assets generate revenue. If maintained through future partnered or approved products, this could support meaningful contribution margins and operating leverage.
Partnered Development ModelThe collaboration-led model can provide milestone, reimbursement, upfront, and potential royalty economics without requiring Atara to fund every commercial activity alone. Strategic partnering may extend development resources and create multiple potential routes to future revenue.
Governance StrengtheningAdding an independent director to the Audit Committee supports board oversight during a financially pressured development period. Continued director independence and shareholder approval of governance matters can improve accountability as the company manages funding and clinical priorities.
Bears Say
Sharp Revenue ContractionA roughly 73% TTM revenue decline shows that reported revenue is highly dependent on collaboration timing and development events rather than a stable recurring base. Continued volatility can weaken operating visibility and make it harder to sustain investment in the pipeline.
Negative Shareholders’ EquityPersistently negative equity signals limited balance-sheet resilience and reduces financial flexibility for a clinical-stage company. With debt present, the position can increase reliance on external funding and constrain the ability to absorb setbacks or pursue programs independently.
Continued Cash BurnOngoing negative operating and free cash flow means the business is not currently self-funding its development activities. Continued cash burn can require additional financing, creating dilution or funding pressure and potentially limiting the pace and scope of pipeline advancement.
Atara Biotherapeutics News
0HIY FAQ
What was Atara Biotherapeutics’s price range in the past 12 months?
Atara Biotherapeutics lowest share price was $4.02 and its highest was $19.05 in the past 12 months.
What is Atara Biotherapeutics’s market cap?
Atara Biotherapeutics’s market cap is $94.15M.
When is Atara Biotherapeutics’s upcoming earnings report date?
Atara Biotherapeutics’s upcoming earnings report date is Oct 29, 2026 which is in 44 days.
How were Atara Biotherapeutics’s earnings last quarter?
Atara Biotherapeutics released its earnings results on Aug 12, 2026. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.315 by -$0.005.
Is Atara Biotherapeutics overvalued?
According to Wall Street analysts Atara Biotherapeutics’s price is currently Undervalued.
Does Atara Biotherapeutics pay dividends?
Atara Biotherapeutics does not currently pay dividends.
What is Atara Biotherapeutics’s EPS estimate?
Atara Biotherapeutics’s EPS estimate is -0.13.
How many shares outstanding does Atara Biotherapeutics have?
Atara Biotherapeutics has 10,037,710 shares outstanding.
What happened to Atara Biotherapeutics’s price movement after its last earnings report?
Atara Biotherapeutics reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.315. Following the earnings report the stock price went down -2.477%.
Which hedge fund is a major shareholder of Atara Biotherapeutics?
Currently, no hedge funds are holding shares in GB:0HIY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atara Biotherapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.50 (74.16% Upside)
$15.50 (74.16% Upside)
Blogger Sentiment
Neutral
GB:0HIY Sentiment 50%
Sector Average 62%
Sector Average 62%
Insider Transactions
Bought Shares
Worth $959.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.86%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-43.03%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Atara Biotherapeutics
Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their primary focus in the United States involves creating treatments for patients battling cancer, autoimmune disorders, and viral infections. A key therapeutic candidate, tabelecleucel, is currently undergoing Phase 3 clinical trials for Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease, as well as various hematologic and solid tumors, such as nasopharyngeal carcinoma. The company is also advancing a robust pipeline of next-generation CAR T immunotherapies designed to combat hematologic malignancies and solid tumors. This includes ATA2271 and ATA3271 targeting mesothelin, alongside ATA2431 and ATA3219 for B-cell malignancies. Furthermore, Atara is developing ATA188 for the treatment of multiple sclerosis and the ATA368 program specifically for cancers associated with human papillomavirus (HPV). To bolster its research and development efforts, Atara Biotherapeutics has established significant collaborations and licensing agreements. These include a licensing partnership with Memorial Sloan Kettering Cancer Center, a license and R&D collaboration with QIMR Berghofer Medical Research Institute, and a strategic alliance with H. Lee Moffitt Cancer Center. Additionally, the company holds a strategic partnership with Bayer AG focused on mesothelin-targeted CAR T-cell therapies for solid tumors.
0HIY Stock 12 Month Forecast
Average Price Target
$15.50
▲(74.16% Upside)